13 January 2026
Boehringer Ingelheim Advances IL-11 Inhibitor to Phase II for IPF
BI 765423, targeting IL-11, enters Phase IIa trials for IPF, aiming to improve lung function. Pre-clinical studies show promise in halting fibrosis and restoring lung functionality.